Author Archives: Jonathan Montagu

About Jonathan Montagu

CEO of HotSpot Therapeutics

Hitting The Spot
November 29, 2021

By Jonathan Montagu, CEO and Co-founder of HotSpot Therapeutics, as part of the From The Trenches feature of LifeSciVC Today marks an important point in our journey to patients as HotSpot Therapeutics announces its $100MM Series C financing.  This infusion

Leave a comment

Immuno-Oncology: The Comeback Kid
July 13, 2021

By Tim Reilly & Jonathan Montagu, CDO and CEO of HotSpot Therapeutics, as part of the From The Trenches feature of LifeSciVC Now 10 years into the golden era of immuno-oncology (I-O) following the first FDA approval of ipilimumab (anti-CTLA4)

Leave a comment

Reimagining The Workplace Post Pandemic
April 15, 2021

By Jonathan Montagu, CEO of HotSpot Therapeutics, as part of the From The Trenches feature of LifeSciVC Returning to work following the pandemic presents an opportunity to think creatively about how to re-configure the workplace.  CEO’s that I have spoken

Leave a comment

The Business Of Science
May 21, 2020

This blog was written by Jonathan Montagu, CEO and co-founder of HotSpot Therapeutics, as part of the From The Trenches feature of LifeSciVC. Today marks an important milestone for HotSpot Therapeutics as we announce our Series B financing, but it

Leave a comment

Cats And The Future Of Machine Learning In Drug Discovery
April 9, 2019

This blog was written by Jonathan Montagu, CEO and founder of HotSpot Therapeutics, as part of the From The Trenches feature of LifeSciVC. The predictions around the impact of artificial intelligence (AI) have been broad reaching but it’s clear that

Leave a comment

Float Like A Butterfly: Agility In Biotech
June 13, 2018

This blog was written by Jonathan Montagu, CEO and co-founder of Hotspot Therapeutics, as part of the From The Trenches feature of LifeSciVC.   In the quest towards building high-performing teams, biopharma can lift a page from the tech playbook around

Leave a comment

Allostery: Realizing The Promise
March 5, 2018

This blog was written by Jonathan Montagu, CEO of Hotspot Therapeutics and Atlas EIR, as part of the From The Trenches feature of LifeSciVC. It starts off with flu-like symptoms and progresses to a perpetual low-grade fever, excessive sweating and

Leave a comment

Target Practice
August 18, 2014

Every life sciences company needs to make good program choices.  Big pharma creates value through smart portfolio management while small biotech companies can be defined by a single lead asset.  In both cases, the opportunity cost of poor decision-making can

Leave a comment

Biotech’s Virtual Reality
June 4, 2014

Much has been written about the merits and demerits of the virtual biotech model.  In essence, a virtual biotech outsources all non-core activities and rejects the need for in-house laboratories.  Instead, a small internal team manages execution outside the company,

3 Comments

Chemistry’s Age of Enlightenment
March 20, 2014

Despite many decades of success, small molecule drug discovery appears to be increasingly challenged.  The likelihood of approval of a small molecule at phase 1 is approximately half that of a biologic; pharma companies have shifted their pipelines dramatically towards

1 Comment